Blog
RSS FeedPosted by Michael Wonder on 01 Sep 2021
Cancer treatments account for 9.3% of total drug claims in 2020
1 September 2021 - The National Health Insurance Service (NHIS) said that the reimbursement claims for anticancer drugs last year ...
Posted by Michael Wonder on 30 Aug 2021
Roche to withdraw 2 Parkinson’s drugs from Korean market
27 August 2021 - Roche said it would withdraw Parkinson’s syndrome treatment Madopar 125 mg and 250 mg tablets from ...
Posted by Michael Wonder on 26 Aug 2021
Government eases criteria for haemophilia A drug reimbursement
26 August 2021 - The Government said it would ease the immune tolerance induction treatment criteria for haemophilia A drug ...
Posted by Michael Wonder on 25 Aug 2021
Avastin biosimilar may bring insurance benefits for Tecentriq
25 August 2021 - The government has been delaying discussing whether to allow reimbursement for Tecentriq (atezolizumab) due to concerns ...
Posted by Michael Wonder on 18 Aug 2021
Talks to recover reimbursement for dementia treatment aid almost complete
18 August 2021 - The negotiations on retrieving the reimbursement of pharmaceutical pricing for choline alfoscerate drugs to help treat ...
Posted by Michael Wonder on 17 Aug 2021
Will Government further expand reimbursement for rare leukaemia drugs?
17 August 2021 - As the Government has gradually increased reimbursement for combination drugs treating chronic lymphocytic leukaemia, patients’ hopes ...
Posted by Michael Wonder on 10 Aug 2021
Companion diagnostics are growing rapidly worldwide. What about in Korea?
10 August 2021 - The global companion diagnostics market is expanding fast, but Korea has yet to develop related technologies, ...
Posted by Michael Wonder on 02 Aug 2021
Novartis’ psoriatic arthritis drug to get expanded reimbursement
2 August 2021 - Novartis Korea said Monday its interleukin-17a inhibitor Cosentyx (secukinumab) began receiving reimbursement as a first-line biologics ...
Posted by Michael Wonder on 28 Jul 2021
'New regulation limiting generic drugs will change industrial paradigm'
27 July 2021 - The Korea Pharmaceutical and Bio-pharma Manufacturers Association said the revision of the Pharmaceutical Affairs Act to ...
Posted by Michael Wonder on 12 Jul 2021
‘MSD Korea proposed unprecedented offer for Keytruda reimbursement’
12 July 2021 - MSD’s Keytruda (pembrolizumab), immunotherapy for lung cancer, is the company’s flagship item that sold $14.38 billion ...
Posted by Michael Wonder on 12 Jul 2021
Leukaemia patients demand reimbursement for Novartis’ Kymriah
12 July 2021 - Korean leukaemia patients have urged the government to provide rapid reimbursement of Kymriah, the first CAR-T ...
Posted by Michael Wonder on 11 Jul 2021
Novartis Korea to continue discussing reimbursement plan for SMA drug Zolgensma
9 July 2021 - Novartis said Friday that it would continue to discuss with the domestic regulators to receive reimbursement ...
Posted by Michael Wonder on 07 Jul 2021
Innovative health technologies need special subsidy
7 July 2021 - Developing innovative health technologies is very important because they can extend human life by broadening the ...
Posted by Michael Wonder on 30 Jun 2021
Sanofi’s Praluent provides solution for Korean dyslipidaemia patients
30 June 2021 - Sanofi Aventis is strengthening its position in the local dyslipidaemia treatment market with Praluent (alirocumab), a ...
Posted by Michael Wonder on 22 Jun 2021
HIRA gives Leclaza benefits easily but delays decision on Tagrisso
22 June 2021 - Yuhan's Leclaza (lazertinib), a third-generation treatment for EGFR mutated non-small cell lung cancer, has won the ...